6.7.8.4. sequencing treatment. 6.7.8.4.1. arpi -> arpi (chemotherapy-naïve mcrpc patients) use sequential arpis mcrpc showed limited benefit retrospective series well one prospective trial [1245-1252]. particular patients short response first arpi mcrpc (< twelve months), sequence avoided known cross resistance availability chemotherapy parp inhibitors (if relevant mutation present). highly selected patients treated 24 weeks aap, sequence enzalutamide showed activity median rpfs 8.1 months (95% ci: 6.1–8.3) unconfirmed psa response rate 27% . case patient unfit chemotherapy parp inhibitor, best supportive care considered case appropriate treatment option available (clinical trial immunotherapy msi-high). arpi-arpi sequence never preferred option might considered patients ps still allows active treatment potential side effects seem manageable. first prospective cross-over data arpi-arpi sequence sr meta-analysis suggest endpoints pfs psa pfs, os, abiraterone followed enzalutamide preferred choice . 6.7.8.4.2. arpi -> parp inhibitor sequence patients deleterious suspected deleterious germline somatic hrr gene-mutated mcrpc supported data randomised phase iii profound trial studying olaparib triton 3 studying rucaparib . subgroup patients profound pre-treated one two arpis chemotherapy (35%). arpi-parp inhibitor sequence versus arpi-arpi arpi-docetaxel patients brca 1/ 2 (and atm) altered tumours studied triton-3 showed significant rpfs benefit favour parp inhibitor following first arpi. data underscore importance early genomic testing mcrpc patients. (see also chapter 6.7.7.5) 6.7.8.4.3. docetaxel mhspc -> docetaxel rechallenge limited evidence second- third-line use docetaxel treatment docetaxel mhspc. docetaxel seems less active arpi progression mcrpc following docetaxel mhspc . 6.7.8.4.4. arpi -> docetaxel docetaxel -> arpi followed parp inhibitor olaparib rucaparib active biomarker-selected mcrpc patients arpi docetaxel either sequence . 6.7.8.4.5. arpi docetaxel level 1 evidence sequences (see table 6.7.3). 6.7.8.4.6. arpi –> docetaxel -> cabazitaxel docetaxel –> arpi -> cabazitaxel third-line treatment sequences supported level 1 evidence. note, high-level evidence favouring cabazitaxel vs. second arpi docetaxel one arpi particular patients progressing ≤ twelve months prior arpi. card first prospective randomised phase iii trial addressing question (see table 6.7.3) . table 6.7.3: randomised controlled phase ii/iii - second-line/third-line trials mcrpc studyinterventioncomparisonselection criteriamain outcomesabirateronecou-aa-3012012 abiraterone + prednisone hrplacebo + prednisone- previous docetaxel.- ecog 0–2.- psa radiographic progression.os: 15.8 vs. 11.2 mo.(p < 0.0001, hr: 0.74, 95%ci: 0.64–0.86; p < 0.0001).fu: 20.2 mo.rpfs: changecou-aa-3012011 os: 14.8 vs. 10.9 mo.(p < 0.001 hr: 0.65; 95%ci: 0.54–0.77).fu: 12.8 mo.rpfs: 5.6 vs. 3.6 mo.radium-223alsympca2013 radium-223placebo- previous previous docetaxel.- ecog 0–2.- two symptomatic bone metastases.- visceral metastases.os: 14.9 vs. 11.3 mo.(p = 0.002, hr: 0.61; 95%ci: 0.46–0.81).all secondary endpoints show benefit best soc.cabazitaxeltropic2013 cabazitaxel + prednisonemitoxantrone + prednisone- previous docetaxel.- ecog 0–2.os: 318/378 vs. 346/377 events(or: 2.11; 95% ci: 1.33–3.33).fu: 25.5 months os > 2 yr 27% vs. 16% pfs: -tropic2010 os: 15.1 vs. 12.7 mo.(p < 0.0001, hr: 0.70;95% ci: 0.59–0.83). fu: 12.8 mo.pfs: 2.8 vs. 1.4 mo.(p < 0.0001, hr: 0.74,95% ci: 0.64-0.86)card2019 cabazitaxel(25 mg/m2 q3w)+ prednisone+ g-csfarta: abiraterone + prednisoneorenzalutamide- previous docetaxel.- progression ≤ 12 mo. prior alternative arpi (either docetaxel)os: 13.6 vs. 11.0 mo.(p = 0.008, hr: 0.64, 95%ci: 0.46–0.89).rpfs 8.0 vs. 3.7 mo.(p < 0.001, hr: 0.54,95% ci: 0.40–0.73).fu: 9.2 mo.enzalutamideaffirm2012 enzalutamideplacebo- previous docetaxel.- ecog 0–2.os: 18.4 vs. 13.6 mo.(p < 0.001, hr: 0.63; 95%ci: 0.53–0.75).fu: 14.4 mo.rpfs: 8.3 vs. 2.9 mo.(hr: 0.40; 95% ci: 0.35–0.47, p < 0.0001).parp inhibitorprofound2020 olaparibabiraterone + prednisolone enzalutamide;cross-over allowed progression- previous arpi,- alterations hrr genesrpfs: 7.39 vs. 3.55 mo.(p < 0.0001, hr: 0.34; 95%ci: 0.25–0.47), conf. orr33.3% vs. 2.3% (or 20.86, 95% ci: 4.18–379.18).os: 19.1 mo vs. 14.7 mo.(in pts brca1/2, atm alterations)(p = 0.0175; hr 0.69, 95%ci: 0.5–0.97).triton-3 rucaparib(600 mg bid)docetaxel abiraterone acetate enzalutamide- eocg 0-1- previous one arpi- brca 1/ 2 atm alterationrpfs: itt10.2 mo vs. 6.4 mo,hr 0.61; 95% ci, 0.47 0.80;(p<0.001 comparisons)radioligand therapyvision2021 177lu-psma-617socsoc alone- previous least 1 arpi one two taxane regimens;- mandatory: psma-positive gallium-68 (68ga)–labelled psma-pet scanimaging-based pfs:8.7 vs. 3.4 mo.(p < 0.001; hr 0.40; 99.2%ci: 0.29–0.57)os: 15.3 vs. 11.3 mo.(p < 0.001; hr 0.62; 95%ci: 0.5–0.74)therap2021 177lu-psma-617(8.5 gbqi.v.q 6-weekly, decreasing0.5 gbq/cycle; 6 cycles)cabazitaxel(20 mg/m2i.v.q 3-weekly, 10 cycles)- post docetaxel,- suitable cabaziaxelfirst endpoint psa reduction > 50%:66 vs. 37 psa responses; 66% vs. 37% itt; difference 29%(95% ci: 16–42; p < 0.0001; 66% vs. 44% treatment received; difference 23% [9–37]; p = 0.0016).secondary endpoint os:19.1 vs. 19.6 mo (177lu-psma vs. cabazitaxel).hr: 0.97, 95% ci: 0.7-1.4(p=0.99) *only studies reporting survival outcomes primary endpoints included.arpi = androgen receptor pathway inhibitor; ci = confidence interval; ecog = eastern cooperative oncology group; fu = follow-up; gbq = gigabecquerel; hr = hazard ratio; lu = lutetium; mo = months os = overall survival; = odds ratio; orr = objective response rate; psa = prostate-specific antigen; psma = prostatespecific membrane antigen; (r)pfs = (radiographic) progression-free survival; soc = standard care; yr = year; hrr= homologous recombination repair.